ELRIG, a not-for-profit organization driven by volunteers and dedicated to the global drug discovery community, has announced the launch of Drug Discovery USA 2026. Scheduled for June 16-17 at Pfizer’s Cambridge, MA facility, this inaugural event aims to foster connections between drug discovery professionals in Europe and the United States. Attendees will engage in discussions surrounding the latest advancements in multifunctional small molecules and innovative biologic modalities that tackle challenging drug targets.
Conference Leadership
To ensure a comprehensive scientific program, ELRIG has appointed a distinguished team of conference directors: Prof. Aled Edwards from the Structural Genomics Consortium, Dr. Marija Tadin-Strapps from Pfizer, and Dr. Swarna Balasubramanian from AstraZeneca. This trio will curate a lineup of leading speakers from both academia and industry to share their expertise and insights.
In collaboration with Pfizer and Drug Discovery News (DDN), ELRIG will host this event on an open-access basis, maximizing accessibility for participants across this new geographical landscape. This approach reinforces ELRIG’s commitment to inclusivity, allowing a broader audience to engage with cutting-edge research and innovations.
Advancements in Drug Discovery
The conference will delve into the latest breakthroughs in chemical biology and protein engineering, which are expanding the potential for pharmacological modulation of proteins. The two-day agenda will highlight multifunctional small molecules and biologic strategies that are transforming early-stage drug discovery. These modern approaches offer versatile platforms designed to manipulate difficult targets through mechanisms that extend beyond simple inhibition, thereby paving the way for new avenues in disease intervention and precision medicine.
Opportunities for Networking and Recognition
A highlight of Drug Discovery USA 2026 will be the Early Career Professionals poster award, designed to showcase the work of emerging scientists. Additionally, an exhibition hall will feature a Breakthrough Zone, where start-up companies can present their innovative science. This environment will foster networking opportunities, allowing participants to connect with a global community of drug discovery professionals.
Bridging Communities
ELRIG Drug Discovery USA represents a significant expansion of the organization’s free-to-attend events, providing US-based scientists with enhanced access to high-quality science and networking opportunities. It also serves as a strategic entry point for international life sciences companies, enabling them to engage with the broader community and share their findings.
Expert Insights
Prof. Aled Edwards, CEO of the Structural Genomics Consortium, expressed enthusiasm for the conference, stating, “Continued innovation in molecular design, delivery, and mechanistic understanding will be critical to fully realize the promise of these next-generation modalities. We look forward to hearing the latest developments from foremost scientists in the field over the two-day conference.”
Dr. Swarna Balasubramanian, Director of Business Development for AstraZeneca’s Respiratory and Immunology division, emphasized the importance of the conference as a platform for the international drug discovery community. She noted, “This scientific conference provides a vital platform for the international drug discovery community to connect with peers across all levels of academia and industry and to share the latest ideas on how cutting-edge small-molecule and biologic approaches are redefining what is druggable.”
Andrea Corona, Senior Editor at DDN, shared her excitement about the event, stating, “DDN is excited to support ELRIG as it expands its renowned open-access events to the United States. This forum will strengthen connections between the European and US drug discovery communities and highlight cutting-edge strategies for tackling challenging targets.”
Conclusion
The launch of Drug Discovery USA 2026 marks an exciting development for the drug discovery landscape, providing a vital platform for collaboration and innovation. As scientists, researchers, and industry leaders converge, the event promises to foster meaningful dialogue and unveil the potential of next-generation therapies. With a focus on enhancing accessibility and promoting knowledge exchange, ELRIG’s inaugural US conference is poised to make a significant impact on the future of drug discovery.
- Key Takeaways:
- ELRIG’s Drug Discovery USA 2026 will take place on June 16-17 at Pfizer in Cambridge, MA.
- The event will feature leading speakers from academia and industry, focusing on innovative drug discovery approaches.
- Networking opportunities and awards for early-career professionals will be highlights of the conference.
- The open-access format aims to enhance participation and collaboration between the US and European drug discovery communities.
Read more → www.news-medical.net